Trial Profile
Longitudinal Imaging Biomarkers of Disease Progression in DLB
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Lewy body disease
- Focus Diagnostic use
- 11 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Sep 2027.
- 11 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Sep 2027.
- 01 Dec 2022 Planned number of patients changed from 90 to 135.